In CLL, activation of the NF-κB pathway contributes to the acquisition of a chemorefractory clinical phenotype and correlates with poor outcome.63–67 The Baculoviral IAP repeat containing 3 (BIRC3) gene is one of the components of a protein complex that negatively regulates the MAP3K14 serin-threonine kinase, the downstream activator of non-canonical NF-κB signaling.63–66. Here, BIRC3 is linked to B-cell chronic lymphocytic leukemia.